Recombinant SATB2 anticorps (AA 200-300)

N° du produit ABIN7871946

L’anticorps anti-SATB2 Monoclonal Lapin est utilisé pour la détection de SATB2 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour Recombinant SATB2 anticorps (AA 200-300) (ABIN7871946)

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp SATB2 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: SATB2-4374R

Détail du produit anti-SATB2 anticorps

Épitope: AA 200-300

Fonction: Recombinant SATB2 Antibody (azide and preservative free)

Purification: Protein A affinity chromatography

Immunogène: A portion of amino acids 200-300 from the human protein was used as the immunogen for the recombinant SATB2 antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the recombinant SATB2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the recombinant SATB2 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur SATB2

Antigène: SATB2 (SATB Homeobox 2 (SATB2))

Autre désignation: SATB2

Sujet: SATB2 (Special AT-rich sequence-binding protein 2) is a DNA binding protein that specifically binds nuclear matrix attachment regions. It is involved in transcription regulation and chromatin remodeling. SATB2 expression in colorectal carcinomas (CRC) is correlated with good prognosis and in laryngeal squamous cell carcinoma it functions as a tumor suppressor wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, it has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.

UniProt: Q9UPW6